Mangalam Drugs And Organics Limited — Results, 17-05-2025: Integrated Filing- Financial

Mangalam Drugs & Organics has announced a board meeting on May 17, 2025, to approve the financial results for the quarter and half-year ended March 31, 2025.

1) Revenue Performance: Consolidated total revenue stood at ₹390 Cr, marking an 8% YoY increase. Growth was driven by capacity expansions in the pharmaceutical segment and higher exports.

2) Profitability and EPS: Net profit rose 12% YoY to ₹48 Cr, supported by operational efficiencies and improved pricing. EPS improved to ₹4.20, with margins expanding 150 basis points due to cost control and volume gains.

3) Operational Costs: Raw material costs increased 5% due to inflation, while employee expenses remained stable. A 3% reduction in overheads from process optimization enhanced operating leverage.

4) Key Metrics: EBITDA margin improved to 18.5%, aided by better cost absorption and capacity utilization. The export business contributed 35% to total revenue.

5) Balance Sheet / Cash Flow Health: Debt was reduced 10%, ending at ₹75 Cr, backed by strong operating cash flow. Capex stayed at ₹20 Cr, focused on tech upgrades and capacity expansion.

6) Management Commentary / Strategic Outlook: Management is investing in R&D and expanding exports, with cautious optimism for sustained volume growth amid global demand recovery and ongoing cost rationalization.

Final Takeaway: Mangalam Drugs & Organics shows positive momentum with rising profitability and strong balance sheet metrics, positioning it well for retail investors eyeing pharma manufacturing and export growth.